American CryoStem Posts Letter to Shareholders
(GlobeNewswire Via Acquire Media NewsEdge) EATONTOWN, N.J., Jan. 6, 2014 (GLOBE NEWSWIRE) -- John Arnone, Chairman and CEO of American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today issued a formal update in the form of a Letter to Shareholders posted to the Company's web site at www.americancryosystem.com.
In the letter, Arnone comments on several key corporate and operational accomplishments achieved by American CryoStem in the past 12 months and on the Company's primary goals and objectives for the coming year. In the letter, Arnone states:
"American CryoStem Corporation is a front runner in the rapidly developing global cell therapy tissue processing and cellular expansion markets. At the core of our business strategy and the foundation of our Company is our state-of-art, FDA-registered (FEI#3008307548), cGMP tissue processing laboratory located in Burlington County, New Jersey. Our laboratory R&D efforts over the last four years have produced significant intellectual property surrounding our cellular processing platform and bio-materials for which we currently have five U.S. patents pending and one patent issued.The issued patent covers our cutting edge method to formulate and manufacture 11 types of stem cell growth and differentiation mediums used in research and cellular therapy. We are in discussions with research universities to develop a unique pipeline of proprietary products and services that we believe target our proposed long term commercial growth strategy: to create standardized tissue processing, clinical grade tissue samples, stem cell samples and bio-materials for use in research and human applications. With 2013 now behind us, I wanted to use this opportunity to inform you on several material developments we believe will positively impact our growth in 2014:
Launch of our tissue storage service ATGRAFT™ and IRB approval of our core processes;
Status of our patented cell growth and differentiation media ACSelerate™;
Establishment of research collaborations with leading research universities and institutions;
Expansion of our Medical & Scientific Advisory Boards & key personnel;
Creation of international relationships for cosmetic and regenerative medicine applications; and
Engagement of an Investment Banking Firm."
To view the CEO letter in its entirety, please go to http://www.americancryostem.com/american-cryostem-letter-to-shareholders/.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage, cell culture and differentiation media development facility in Mount Laurel, New Jersey.
For more information, please visit www.americancryostem.com and www.acslaboratories.com.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
Kathy Addison, Chief Operating Officer
407-585-1080 or via email at CRYO@hanoverelite.com
Source: American CryoStem Corp.
2014 GlobeNewswire, Inc.
[ Back To TMCnet.com's Homepage ]